A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis

Biochemical and Biophysical Research Communications

Volumn 416, Issue 1-2, 2011, Pages 7-12

  Chattopadhyay, Amitabha ^a   Jafurulla, Md ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

Amphotericin B; Host macrophage; Leishmania donovani; Membrane cholesterol; Pathogen entry; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; CHOLESTEROL; ERGOSTEROL;

CHEMICAL STRUCTURE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; HOST PARASITE INTERACTION; LEISHMANIA DONOVANI; MACROPHAGE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT PLANNING; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CELL MEMBRANE; CHOLESTEROL; HUMANS; LEISHMANIA; LEISHMANIASIS, VISCERAL; MACROPHAGES;

LEISHMANIA DONOVANI;

EID: 83055160881     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.11.023     Document Type: Short Survey

References (65)

1. Herwaldt B.L. Leishmaniasis. Lancet 1999, 354:1191-1199.
2. Alexander J., Satoskar A.R., Russell D.G. Leishmania species: models of intracellular parasitism. J. Cell Sci. 1999, 112:2993-3002.
3. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., Alvar J., Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat. Rev. Microbiol. 2007, 5:873-882.
4. World Health Organization. Website: http://www.who.int/leishmaniasis/en/.
5. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
6. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27:305-318.
7. Singh S.P., Reddy D.C., Rai M., Sundar S. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop. Med. Int. Health 2006, 11:899-905.
8. Wolday D., Berhe N., Akuffo H., Britton S. Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol. Today 1999, 15:182-187.
9. Handman E., Bullen D.V.R. Interaction of Leishmania with the host macrophage. Trends Parasitol. 2002, 18:332-334.
10. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2002, 2:845-858.
11. Rittig M.G., Bogdan C. Leishmania-host-cell interaction: complexities and alternative views. Parasitol. Today 2000, 16:292-297.
12. Sacks D., Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu. Rev. Microbiol. 2001, 55:453-483.
13. Rosenberger C.M., Brumell J.H., Finlay B.B. Microbial pathogenesis: lipid rafts as pathogen portals. Curr. Biol. 2000, 10:R823-R825.
14. Shin J.-S., Abraham S.N. Caveolae as portals of entry for microbes. Microbes Infect. 2001, 3:755-761.
15. van der Goot F.G., Harder T. Raft membrane domains: from a liquid-ordered membrane phase to a site of pathogen attack. Semin. Immunol. 2001, 13:89-97.
16. Simons K., Ehehalt R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 2002, 110:597-603.
17. Bansal D., Bhatti H.S., Sehgal R. Role of cholesterol in parasitic infections. Lipids Health Dis. 2005, 4:10.
18. Goluszko P., Nowicki B. Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cells. Infect. Immun. 2005, 73:7791-7796.
19. Hawkes D.J., Mak J. Lipid membrane; a novel target for viral and bacterial pathogens. Curr. Drug Targets 2006, 7:1615-1621.
20. Riethmüller J., Riehle A., Grassmé H., Gulbins E. Membrane rafts in host-pathogen interactions. Biochim. Biophys. Acta 2006, 1758:2139-2147.
21. Pucadyil T.J., Chattopadhyay A. Cholesterol: a potential therapeutic target in Leishmania infection?. Trends Parasitol. 2007, 23:49-53.
22. Vieira F.S., Corrêa G., Einicker-Lamas M., Coutinho-Silva R. Host-cell lipid rafts: a safe door for micro-organisms?. Biol. Cell. 2010, 102:391-407.
23. Pucadyil T.J., Chattopadhyay A. Role of cholesterol in the function and organization of G-protein coupled receptors. Prog. Lipid Res. 2006, 45:295-333.
24. Gimpl G. Cholesterol-protein interaction: methods and cholesterol reporter molecules. Subcell. Biochem. 2010, 51:1-45.
25. Paila Y.D., Chattopadhyay A. Membrane cholesterol in the function and organization of G-protein coupled receptors. Subcell. Biochem. 2010, 51:439-466.
26. Harrison T., Samuel B.U., Akompong T., Hamm H., Mohandas N., Lomasney J.W., Haldar K. Erythrocyte G protein-coupled receptor signaling in malarial infection. Science 2003, 301:1734-1736.
27. Pucadyil T.J., Tewary P., Madhubala R., Chattopadhyay A. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol. Biochem. Parasitol. 2004, 133:145-152.
28. Tewary P., Veena K., Pucadyil T.J., Chattopadhyay A., Madhubala R. The sterol-binding antibiotic nystatin inhibits entry of non-opsonized Leishmania donovani into macrophages. Biochem. Biophys. Res. Commun. 2006, 339:661-666.
29. Paila Y.D., Saha B., Chattopadhyay A. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Biochem. Biophys. Res. Commun. 2010, 399:429-433.
30. Rodríguez N.E., Gaur U., Wilson M.E. Role of caveolae in Leishmania chagasi phagocytosis and intracellular survival in macrophages. Cell. Microbiol. 2006, 8:1106-1120.
31. Mondal S., Bhattacharya P., Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev. Anti. Infect. Ther. 2010, 8:919-944.
32. Sundar S., Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 2006, 123:345-352.
33. Wasan K.M., Wasan E.K., Gershkovich P., Zhu X., Tidwell R.R., Werbovetz K.A., Clement J.G., Thornton S.J. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J. Infect. Dis. 2009, 200:357-360.
34. Cohen B.E., Ramos H., Gamargo M., Urbina J. The water and ionic permeability induced by polyene antibiotics across plasma membrane vesicles from Leishmania sp. Biochim. Biophys. Acta 1986, 860:57-65.
35. Torrado J.J., Espada R., Ballesteros M.P., Torrado-Santiago S. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 2008, 97:2405-2425.
36. J.D. Dutcher, W. Gold, J.F. Pagano, J. Vandepatte, Amphotericin B, its production and its salts, US patent 2908,611, 1959.
37. Cohen B.E. Amphotericin B toxicity and lethality: a tale of two channels. Int. J. Pharm. 1998, 162:95-106.
38. Lemke A., Kiderlen A.F., Kayser O. Amphotericin B. Appl. Microbiol. Biotechnol. 2005, 68:151-162.
39. Berman J.D., Ksionski G., Chapman W.L., Waits V.B., Hanson W.L. Activity of amphotericin B cholesterol dispersion (amphocil) in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 1992, 36:1978-1980.
40. Legrand P., Chéron M., Leroy L., Bolard J. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J. Drug Target 1997, 4:311-319.
41. Larabi M., Yardley V., Loiseau P.M., Appel M., Legrand P., Gulik A., Bories C., Croft S.L., Barratt G. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob. Agents Chemother. 2003, 47:3774-3779.
42. Wu W., Wieckowski S., Pastorin G., Benincasa M., Klumpp C., Briand J.-P., Gennaro R., Prato M., Bianco A. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew. Chem., Int. Ed. 2005, 44:6358-6362.
43. Prajapati V.K., Awasthi K., Gautam S., Yadav T.P., Rai M., Srivastava O.N., Sundar S. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J. Antimicrob. Chemother. 2011, 66:874-879.
44. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 1990, 12:308-329.
45. Moen M.D., Lyseng-Williamson K.A., Scott L.J. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009, 69:361-392.
46. Croft S.L., Davidson R.N., Thornton E.A. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob. Chemother. 1991, 28(Suppl. B):111-118.
47. Sundar S., Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. J. Glob. Infect. Dis. 2010, 2:159-166.
48. M.D. Houslay, K.K. Stanley, Dynamics of biological membranes: influence on synthesis, structure and function, John Wiley, New York, 2009, p. 289.
49. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties?. Biochim. Biophys. Acta 1986, 864:257-304.
50. Hartsel S., Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol. Sci. 1996, 17:445-449.
51. Neumann A., Czub J., Baginski M. On the possibility of the amphotericin B-sterol complex formation in cholesterol- and ergosterol-containing lipid bilayers: a molecular dynamics study. J. Phys. Chem. B 2009, 113:15875-15885.
52. Baginski M., Resat H., McCammon J.A. Molecular properties of amphotericin B membrane channel: a molecular dynamics simulation. Mol. Pharmacol. 1997, 52:560-570.
53. Baginski M., Sternal K., Czub J., Borowski E. Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic. Acta Biochim. Pol. 2005, 52:655-658.
54. De Kruijff B., Demel R.A. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes: III. Molecular structure of the polyene antibiotic-cholesterol complexes. Biochim. Biophys. Acta 1974, 339:57-70.
55. Kleinberg M.E., Finkelstein A. Single-length and double-length channels formed by nystatin in lipid bilayer membranes. J. Membr. Biol. 1984, 80:257-269.
56. Cohen B.E. Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects. J. Membr. Biol. 2010, 238:1-20.
57. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 1996, 9:512-531.
58. Barratt G., Legrand P. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr. Opin. Infect. Dis. 2005, 18:527-530.
59. Bekersky I., Fielding R.M., Dressler D.E., Lee J.W., Buell D.N., Walsh T.J. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 2002, 46:834-840.
60. 1A receptors from bovine hippocampus. Biochim. Biophys. Acta 2004, 1663:188-200.
61. Zidovetzki R., Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim. Biophys. Acta 2007, 1768:1311-1324.
62. Readio J.D., Bittman R. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochim. Biophys. Acta 1982, 685:219-224.
63. Mouri R., Konoki K., Matsumori N., Oishi T., Murata M. Complex formation of amphotericin B in sterol-containing membranes as evidenced by surface plasmon resonance. Biochemistry 2008, 47:7807-7815.
64. Saha A.K., Mukherjee T., Bhaduri A. Mechanism of action of amphotericin B on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 1986, 19:195-200.
65. Berman J.D., Hanson W.L., Chapman W.L., Alving C.R., Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 1986, 30:847-851.